SGLT-2抑制剂研究进展

Progress in Sodium Glucose Co-transporter 2 Inhibitors

钠-葡萄糖协同转运蛋白抑制剂具有独特的不依赖于胰岛素分泌的降糖途径,使过量的葡萄糖从尿液中排出,进而降低血糖。因其作用机制,该药在2型糖尿病(type 2 diabetes mellitus,T2DM)任何阶段均可使用。除降糖作用外,该类药物已被证实具有减轻体重、血压、尿白蛋白/肌酐比值,还被证实能降低不良心血管疾病风险。目前研究表明,钠-葡萄糖协同转运蛋白抑制剂具有良好的药效和耐受性,可成为2型糖尿病患者新的药物选择。

Sodium glucose co-transporter 2 （SGLT-2） inhibitors have a unique mechanism of action leading to excretion of glucose in the urine and subsequent lowering of plasma glucose. This mechanism is independent of β-cell function; thus, these agents are effective treatment for type 2 diabetes mellitus （T2DM） at theoretically any disease stage, in addition to its glucose-lowering effects, this class has been shown to reduce body weight and blood pressure, urinary albumin/creatinine ratio （UACR）. Moreover, it had been demonstrated to reduce relative risk in major adverse cardiac events. The efficacy and safety data from the present analysis suggest that SGLT-2 can be an effective and well-tolerated therapeutic option in T2DM patients.